Colon-targeted delivery of α-terpineol via ZIF-8 alleviates ulcerative colitis by anti-inflammatory and gut microbiota-metabolism modulation.
Ulcerative colitis (UC) demands lifelong therapy, yet current regimens require daily high-dose administration that drives poor adherence and cumulative toxicity. Although α-terpineol (αTL) shows therapeutic efficacy in colitis, its oral application is limited by poor oral bioavailability and a lack of colon specificity...